Q: What is the highest development stage achieved for this compound across all indications? Please respond with Approved, Phase 3 Clinical Trials, Phase 2 Clinical Trials, Phase 1 Clinical Trials, Early Phase 1 Clinical Trials, or Clinical Phase Unknown.
Constraint: The Molecule can be represented with the SMILES CC(=O)N1CCC(NC(=O)NC23CC4CC(CC(C4)C2)C3)CC1.
Result: Phase 2 Clinical Trials
{#Question|Q!}: {quest#}
{#Constraint:|Description:|!} The {#Molecule|Compound|Chemical!} {#has the|can be represented with the!} {SMILES__description} {SMILES#}.
{#Answer|Result|Answer!}: {answ#}
CC(=O)N1CCC(NC(=O)NC23CC4CC(CC(C4)C2)C3)CC1
CC(=O)N1CCC(NC(=O)NC23CC4CC(CC(C4)C2)C3)CC1
1-(1-acetylpiperidin-4-yl)-3-(1-adamantyl)urea
What is the highest development stage achieved for this compound across all indications? Please respond with Approved, Phase 3 Clinical Trials, Phase 2 Clinical Trials, Phase 1 Clinical Trials, Early Phase 1 Clinical Trials, or Clinical Phase Unknown.